Quantcast

Latest Telik Inc. Stories

2014-09-09 08:32:44

Board of Directors Sets Reverse Split Ratio at 8 to 1 and Approves Capital Structure Improvements SAN DIEGO, Sept. 9, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a publicly-traded clinical stage cancer immunotherapy company, announced today that stockholders have approved a change in the Company's name from Telik, Inc. to MabVax Therapeutics Holdings Inc., as well as a change in ticker symbol to MBVX that will likely take effect within the next three weeks....

2014-08-28 12:29:01

Key Program Part of Recent Merger with MabVax Therapeutics, Inc. SAN DIEGO, Aug. 28, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has made significant progress related to the development of its lead antibody program designated 5B1. The fully-human antibody was recovered using the Company's internally developed antibody discovery platform. These...

2014-08-25 12:26:05

Contract Results from Recent Merger with MabVax Therapeutics, Inc. SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has received a $1.5 million contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The contract is intended to support a major portion of the...

2014-08-11 08:29:39

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, which recently merged with MabVax Therapeutics, Inc. on July 8, 2014, announced the appointment of six new members of the board of directors to help guide the company and its management in developing an expanded product development pipeline post-merger. "We are pleased to be able to attract such an outstanding new slate of board members who have both strong...

2014-08-04 08:29:16

SAN DIEGO, Aug. 4, 2014 /PRNewswire/ -- As previously announced, MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. (OTCQB: TELK), aclinical stage oncology drug development company, completed a merger transaction pursuant to which MabVax became a wholly owned subsidiary of Telik effective as of July 8, 2014, following Telik stockholder approval at Telik's annual meeting of stockholders, held on July 7, 2014. Following the merger, MabVax...

2014-05-15 16:28:36

PALO ALTO, Calif., May 15, 2014 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2014. The net loss for the quarter ended March 31, 2014 was $1.1 million, or $0.23 per share, compared with a net loss of $1.9 million, or $0.46 per share, for the same period in 2013. Total research and development expenses (R&D) in the first quarter of 2014 were $0.3 million, compared to $0.8 million for the same period in 2013....

2014-05-12 16:29:32

PALO ALTO, Calif., May 12, 2014 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK), a clinical stage oncology drug development company, and MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, have entered into a definitive merger agreement. Upon closing of the transaction, MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. Under the terms of the merger...

2014-05-12 16:29:28

SAN DIEGO, May 12, 2014 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held cancer immunotherapy company and Telik, Inc. (Nasdaq: TELK), aclinical stage oncology drug development company have entered into a definitive merger agreement. Upon closing of the transaction, MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. Under the terms of the merger agreement,...

2014-03-10 16:33:03

PALO ALTO, Calif., March 10, 2014 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $0.8 million, or $0.17 per share, for the three months ended December 31, 2013, compared with a net loss of $1.8 million, or $0.66 per share, for the comparable period in 2012. For the year ended December 31, 2013, net loss was $5.2 million, or $1.17 per share, compared with a net loss of $8.0 million, or $3.64 per share, for the year ended December 31, 2012. For the quarter ended December...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related